{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T04:48:38Z","timestamp":1789879718356,"version":"4.0.1"},"reference-count":36,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2008,6,28]],"date-time":"2008-06-28T00:00:00Z","timestamp":1214611200000},"content-version":"vor","delay-in-days":4868,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Eur J Clin Investigation"],"published-print":{"date-parts":[[1995,3]]},"abstract":"<jats:p><jats:bold>Abstract. <\/jats:bold> The present prospective, randomized, multicentre study was performed to directly compare for the first time the effectiveness of a standard activity of 555 MBq <jats:sup>131<\/jats:sup> iodine vs. an activity calculated to deliver 100 Gy for treatment of Graves' thyro\u2010toxicosis. Therapeutic success was defined as the elimination of hyperthyroidism 6 months after radio\u2010iodine application (range 4.5\u20138 months). A success rate of more than 90% in eliminating hyperthyroidism was reported for both approaches, but only in retrospective investigations. Investigated prospec\u2010tively, hyperthyroidism was eliminated in only 71% of the patients receiving standard activity (70\/98) and 58% of those randomized for calculated activity (62\/107). In the patients with standard activity, therapeutic success was inversely related to thyroid size. The rate was 100% for thyroid volumes \u226415 mL, 95% for 16\u201330 mL, 68% for 31\u201345 mL, 44% for 46\u201350 mL, 20% for 61\u201375 mL and 25% for \u226575 mL. In those patients with an activity calculated to deliver 100 Gy (except in those with a volume \u226515 mL) this size\/outcome dependency was almost compensated. The rates were 86%, 65%, 45%, 61%, 41% and 45%, respectively. Furthermore, detailed statistical analysis revealed a strong correlation between the success of therapy and the radiation dose actually absorbed by the thyroid. The rate was 11 % for a target dose of 50Gy, 50% for 100 Gy, 67% for 150Gy, 80 % for 200 Gy, 84 % for 250 Gy, 88 % for 300 Gy, 90 % for 350 Gy and 93% for 400 Gy. Based on the results obtained in the present study, we strongly recommend individual calculation of the<jats:sup>131<\/jats:sup> iodine activity to be administered for treatment of Graves' hyperthyroidism. However, the target dose should be in the range of 200Gy.<\/jats:p>","DOI":"10.1111\/j.1365-2362.1995.tb01547.x","type":"journal-article","created":{"date-parts":[[2008,3,20]],"date-time":"2008-03-20T12:14:46Z","timestamp":1206015286000},"page":"186-193","source":"Crossref","is-referenced-by-count":135,"title":["Radioiodine therapy of Graves' hyperthyroidism: standard vs. calculated <sup>131<\/sup> iodine activity*. Results from a prospective, randomized, multicentre study"],"prefix":"10.1111","volume":"25","author":[{"given":"H.","family":"PETERS","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"FISCHER","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"U.","family":"BOGNER","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"REINERS","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"SCHLEUSENER","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2008,6,28]]},"reference":[{"key":"e_1_2_1_2_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199104043241410"},{"key":"e_1_2_1_3_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-0029-1211072"},{"key":"e_1_2_1_4_2","first-page":"689","article-title":"Prospective multicentre study on the prediction of relapse after anti\u2010thyroid drug treatment in patients with Graves' disease","volume":"120","author":"Schleusener H.","year":"1989","journal-title":"Acta Endocrinol Copenh"},{"key":"e_1_2_1_5_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198408163110710"},{"key":"e_1_2_1_6_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2265.1991.tb03523.x"},{"key":"e_1_2_1_7_2","doi-asserted-by":"publisher","DOI":"10.5694\/j.1326-5377.1971.tb88071.x"},{"key":"e_1_2_1_8_2","doi-asserted-by":"publisher","DOI":"10.1210\/jcem-38-6-976"},{"key":"e_1_2_1_9_2","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1093\/oxfordjournals.aje.a114900","article-title":"Radioactive iodine therapy and breast cancer. A follow\u2010up study of hyperthyroid women","volume":"127","author":"Goldman MB","year":"1988","journal-title":"Am J Epidemiol"},{"key":"e_1_2_1_10_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/83.15.1072"},{"key":"e_1_2_1_11_2","first-page":"63","article-title":"Treatment of thyrotoxicosis with 131I","volume":"63","author":"Blomfield GW","year":"1957","journal-title":"B M J"},{"key":"e_1_2_1_12_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.129.1.33"},{"key":"e_1_2_1_13_2","first-page":"978","article-title":"Radioiodine\u2010induced hypothyroidism in Graves' disease: Factors associated with the increasing incidence","volume":"23","author":"Cunnien AJ","year":"1982","journal-title":"J Nucl Med"},{"key":"e_1_2_1_14_2","first-page":"323","article-title":"HLA\u2010DR3 and DRw6: prognostic factors for the incidence of hypothyroidism in Graves' disease after radioiodine treatment","volume":"113","author":"Althaus B.","year":"1986","journal-title":"Acta Endocrinol Copenh"},{"key":"e_1_2_1_15_2","doi-asserted-by":"publisher","DOI":"10.1507\/endocrj1954.36.359"},{"key":"e_1_2_1_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0009-9260(05)81624-1"},{"key":"e_1_2_1_17_2","first-page":"158","article-title":"[Results of radioiodine therapy of manifest hyperthyroidism and autonomous struma with euthyroidismj","volume":"29","author":"Berding G.","year":"1990","journal-title":"Nuklearmedizin"},{"key":"e_1_2_1_18_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199206253262603"},{"key":"e_1_2_1_19_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM196709142771102"},{"key":"e_1_2_1_20_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.135.5.673"},{"key":"e_1_2_1_21_2","first-page":"135","article-title":"Factors predicting hypothyroidism in long\u2010term follow\u2010up after 131I therapy","volume":"27","author":"Gimlette TMD","year":"1988","journal-title":"Nucl Med"},{"key":"e_1_2_1_22_2","first-page":"519","article-title":"Iodine\u2010131 treatment of Graves' disease using modified early iodine\u2010131 uptake measurements in therapy dose calculations","volume":"31","author":"Hayes AA","year":"1990","journal-title":"J Nucl Med"},{"key":"e_1_2_1_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(75)92071-1"},{"key":"e_1_2_1_24_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.289.6441.361"},{"key":"e_1_2_1_25_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1748-1716.1985.tb07692.x"},{"key":"e_1_2_1_26_2","doi-asserted-by":"publisher","DOI":"10.1210\/jcem-62-4-773"},{"key":"e_1_2_1_27_2","doi-asserted-by":"publisher","DOI":"10.1259\/0007-1285-59-707-1105"},{"key":"e_1_2_1_28_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2265.1991.tb00280.x"},{"key":"e_1_2_1_29_2","first-page":"103","article-title":"Is standard 555 MBq 131I\u2010therapy of hyperthyroidism ablative","volume":"4","author":"Bertelsen J.","year":"1992","journal-title":"Thyroidol Clin Exp"},{"key":"e_1_2_1_30_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2265.1988.tb03683.x"},{"key":"e_1_2_1_31_2","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1177\/014107688507801103","article-title":"Low\u2010dose radioiodine given six\u2010monthly in Graves' disease","volume":"78","author":"Hoskin PJ","year":"1985","journal-title":"J R Soc Med"},{"key":"e_1_2_1_32_2","first-page":"265","volume-title":"Nuclear Medicine Annual","author":"Becker DV","year":"1984"},{"key":"e_1_2_1_33_2","doi-asserted-by":"publisher","DOI":"10.1210\/jcem-47-2-379"},{"key":"e_1_2_1_34_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198408163110702"},{"key":"e_1_2_1_35_2","first-page":"494","article-title":"Goitre epidemiology: thyroid volume, iodine excretion, thyroglobulin and thyrotropin in Germany and Sweden","volume":"112","author":"Gutekunst R.","year":"1986","journal-title":"Acta Endocrinol Copenh"},{"key":"e_1_2_1_36_2","first-page":"888","article-title":"Diagnosis and management of large toxic multinodular goiters","volume":"26","author":"Hamburger JI","year":"1985","journal-title":"J Nucl Med"},{"key":"e_1_2_1_37_2","first-page":"885","article-title":"Graves' disease with functioning nodules (Marine\u2010Lenhart syndrome)","volume":"13","author":"Charkes ND.","year":"1972","journal-title":"J Nucl Med"}],"container-title":["European Journal of Clinical Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2362.1995.tb01547.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2362.1995.tb01547.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,25]],"date-time":"2023-10-25T14:11:51Z","timestamp":1698243111000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2362.1995.tb01547.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1995,3]]},"references-count":36,"journal-issue":{"issue":"3","published-print":{"date-parts":[[1995,3]]}},"alternative-id":["10.1111\/j.1365-2362.1995.tb01547.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2362.1995.tb01547.x","archive":["Portico"],"relation":{},"ISSN":["0014-2972","1365-2362"],"issn-type":[{"value":"0014-2972","type":"print"},{"value":"1365-2362","type":"electronic"}],"subject":[],"published":{"date-parts":[[1995,3]]}}}